We receive many emails enquiring about progress. As answering these takes time away from processing submissions, please email only if absolutely necessary. We are working hard to process registration and update requests as quickly as possible.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Date data sharing statement initially provided
Date results information initially provided
Type of registration
Retrospectively registered

Titles & IDs
Public title
Strain sUrveillance during Chemotherapy for improving Cardiovascular OUtcomes
Scientific title
Randomised controlled trial (RCT) of chemotherapy patients at risk of cardiotoxicity undergoing cardioprotection guided by measurement of LV strain compared with cardioprotection guided by measurement of left ventricular (LV) ejection fraction for avoidance of cardiotoxicity
Secondary ID [1] 284309 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cardiotoxicity from cancer chemotherapy 291458 0
Condition category
Condition code
Cardiovascular 291828 291828 0 0
Other cardiovascular diseases
Cancer 291862 291862 0 0
Any cancer

Study type
Description of intervention(s) / exposure
Inclusion of myocardial mechanics in screening echocardiography for development of cardiotoxicity. Serial screening test for LV strain is envisaged at 3 monthly intervals for a year and the acquisition takes ~30 minutes.
Intervention code [1] 289032 0
Early detection / Screening
Comparator / control treatment
Performance of standard echocardiogram, an ultrasound test of the heart where ejection fraction (EF) is measured. This is an insensitive test for early changes, but is used to ensure that patients with possible cardiotoxicity are managed safely. This screening test is envisaged at 3 monthly intervals for a year and the acquisition takes ~30 minutes.
Control group

Primary outcome [1] 291747 0
New LV dysfunction, defined on the basis of 3D echo.
Timepoint [1] 291747 0
Assessed at 3 years post randomisation.
Primary outcome [2] 291776 0
New heart failure (HF), assessed on the basis of clinical diagnosis of HF.
Timepoint [2] 291776 0
Assessed at 3 years post randomisation.
Secondary outcome [1] 307403 0
Development of cardiotoxicity – ie a categorical analysis of reduced 3D echocardiographic LVEF concordant with the recent guidelines (reduction of LVEF of more than 5% to less than 55% with symptoms of heart failure, or an asymptomatic reduction of LVEF of more than 10% to less than 55%).
Timepoint [1] 307403 0
Assessed at 3 years post randomisation
Secondary outcome [2] 307404 0
Rate of completion of the planned chemotherapy among groups, defined by audit of prescribed drug prescription in patient records
Timepoint [2] 307404 0
Assessed at 3 years post randomisation
Secondary outcome [3] 307405 0
Rate of heart failure among groups, defined by clinical HF diagnosis in patient record.
Timepoint [3] 307405 0
Assessed at 3 years post randomisation

Key inclusion criteria
i. Patients actively undergoing chemotherapy at increased risk of cardiotoxicity;
use of anthracycline WITH current (but not necessarily concurrent)
trastuzumab (Herceptin) in breast-cancer with the HER2 mutation OR
tyrosine kinase inhibitors (eg sunitinib) OR
cumulative anthracycline dose >450g/m2 of doxorubicin, or equivalent other anthracycline cumulative dose (eg for epirubicine >900g/m2).OR
increased risk of HF (any two of age >65y, type 2 diabetes mellitus, hypertension, previous cardiac injury eg. myocardial infarction)
ii. Live within a geographically accessible area for follow-up
iii. Are able and willing to provide written informed consent to participate in the study (this includes the ability to communicate fluently with the investigator and that the patient is mentally competent)
Minimum age
18 Years
Maximum age
80 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
- Unable to provide written informed consent to participate in this study
- Participating in another clinical research trial where randomized treatment would be unacceptable
- Valvular stenosis or regurgitation of >moderate severity
- History of previous heart failure (baseline NYHA >2)
- Systolic BP <110mmHg
- Pulse <60/minute
- Inability to acquire interpretable images (identified from baseline echo)
- Contraindications/Intolerance to beta blockers or ACE inhibitors
- Existing therapy with both beta blockers and ACE inhibitors
- Oncologic (or other) life expectancy <12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
At risk subjects will be identified by cardiologists, oncologists, general practitioners, or self-referred. We plan to compare 138 subjects with strain vs 138 controls.

Clinical evaluation: All subjects will undertake a clinical history and answer questionnaires on general health status (EQ5D), activity (DASI) and heart failure symptoms (MLHFQ). All will undergo a screening echo for valvular disease. If these results are abnormal, subjects will be excluded.

Study protocol: A central (web-based) randomization program will be used to allocate patients to advanced vs conventional imaging only after the patient is enrolled. This allocation concealment will prevent the person performing recruitment from knowing the allocated group at the time of inclusion. Subsequent management decisions are not based on randomization and will occur as a "usual care' response to data provided from imaging.

Conventional imaging: Limited to evaluation of EF and valve disease. If there is a symptomatic drop of more than 5% of ejection fraction, or a 10% asymptomatic drop of ejection fraction to EF <55% will lead to referral of the patient for initiation and titration of heart failure therapy.

Advanced cardiac imaging: Inclusion of global longitudinal strain. Reduction of global longitudinal strain by >12% in any of the follow-up echocardiograms, as compared to baseline will lead to referral of the patient for initiation and titration of heart failure therapy(see below).
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomisation will be performed using a randomisation table created by computer software (i.e. computerised sequence generation). Randomization is stratified on the basis of diabetes status.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other design features
Those with an abnormal test will be identified as having Stage B heart failure, and undergo better blood pressure and glucose control. Additional protective therapy (ACE inhibitors and beta blockers) will be added and titrated to target dose.
Not Applicable
Type of endpoint(s)
Statistical methods / analysis
Power calculations; Assumptions –
1) cutoff for strain = 11% decrement (Negishi JASE 2014)
2) cutoff for EF = 10% asympt drop to <55% (Seidman AD, JCO 2002)
3) reduction in EF in at risk patients at 3m = 21% (Sawaya, AJC 2011)
4) response to medical Rx in patients with reduced EF=40% (from Cardinale).
5) development of HF in 41% at 3y (from Chen, JACC 2013).
6) reduction in strain in at risk patients = 34% (from submitted “3 toxic regimen” paper by Negishi, using 11% reduction strain).
7) response to therapy based on strain = 90% (from submitted “3 toxic regimen” paper by Negishi, based on 11% reduction strain).% (unpublished observation).
8) Reduction in EF of patients with reduced strain = 14% (from prelim data).

Calculations –These are based on the development of cardiotoxicity in patients with preserved EF. Based on these assumption of 24 vs 40 patients showing cardiotoxicity, a study of 138 patients/group would give 80% power to identify a difference at p<0.05 using an intention-to-treat approach. To allow for drop-outs we will recruit 320 patients.

Primary data analysis will compare the outcomes of patients will be compared with a t-test (change in EF) or survival analysis (heart failure and cessation of treatment). Multivariable models (respectively linear and Cox regression) will be developed to identify effect size, and will be extremely important if groups are mismatched despite randomization. All analyses will be performed on an intention to treat basis. Subsequent analyses will include the same methods to compare differences in the secondary end-points.

The data from all participating investigational sites will be pooled and summarised with respect to demographic and baseline characteristics. Exploratory data analyses will be performed using descriptive statistics. Data will be presented for the complete intent-to-treat (ITT) population (all patients having taken part in a significant proportion of the study but did not complete follow-up data collection and/or had major protocol deviations) as well as the per-protocol population (ITT patients who completed the study).

Survival curves will be constructed using time-dependent, all-cause survival and event-free survival data for all patients on an ITT basis followed by log-rank and Breslow tests to determine differences between groups with respect to the number and/or timing of events. To examine the interactions between risk factors and treatment mode and other potential correlates of event-free survival and all-cause mortality during study follow-up we will construct Cox-Proportional Hazards Models with calculation of relative risk (RR) and 95% confidence interval. Multiple logistic regressions will be used to determine independent correlates of clinical events at fixed time-points.

Recruitment status
Active, not recruiting
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 2224 0
Royal Hobart Hospital - Hobart
Recruitment hospital [2] 2226 0
Monash Medical Centre - Clayton campus - Clayton
Recruitment hospital [3] 5352 0
St Vincent's Hospital (Melbourne) Ltd - Fitzroy
Recruitment hospital [4] 5353 0
The Alfred - Prahran
Recruitment hospital [5] 14602 0
The Royal Adelaide Hospital - Adelaide
Recruitment hospital [6] 14603 0
Westmead Hospital - Westmead
Recruitment postcode(s) [1] 7904 0
7000 - Hobart
Recruitment postcode(s) [2] 7906 0
3168 - Clayton
Recruitment postcode(s) [3] 12806 0
3065 - Fitzroy
Recruitment postcode(s) [4] 12807 0
3004 - Melbourne
Recruitment postcode(s) [5] 27622 0
5000 - Adelaide
Recruitment postcode(s) [6] 27623 0
2145 - Westmead
Recruitment outside Australia
Country [1] 5913 0
State/province [1] 5913 0
Country [2] 5914 0
State/province [2] 5914 0
Country [3] 5915 0
State/province [3] 5915 0
Country [4] 5916 0
State/province [4] 5916 0
Country [5] 7617 0
State/province [5] 7617 0
Country [6] 7618 0
State/province [6] 7618 0
Country [7] 7619 0
Korea, Republic Of
State/province [7] 7619 0
Country [8] 7620 0
State/province [8] 7620 0
Country [9] 7621 0
United States of America
State/province [9] 7621 0
Country [10] 7622 0
Russian Federation
State/province [10] 7622 0
Central Federal District
Country [11] 21778 0
State/province [11] 21778 0
Country [12] 21779 0
State/province [12] 21779 0
Country [13] 21780 0
State/province [13] 21780 0
Country [14] 21781 0
State/province [14] 21781 0
Country [15] 21782 0
State/province [15] 21782 0
Country [16] 21783 0
State/province [16] 21783 0
Country [17] 21784 0
State/province [17] 21784 0
Country [18] 21785 0
State/province [18] 21785 0
Country [19] 21786 0
State/province [19] 21786 0
Country [20] 21787 0
State/province [20] 21787 0
Country [21] 21788 0
United States of America
State/province [21] 21788 0
Country [22] 21789 0
State/province [22] 21789 0

Funding & Sponsors
Funding source category [1] 288950 0
Commercial sector/Industry
Name [1] 288950 0
GE Medical Systems
Address [1] 288950 0
GE Vingmed Ultrasound AS
Strandpromenaden 45, box 141
Horten 3188
Country [1] 288950 0
Primary sponsor type
Menzies Research Institute Tasmania
17 Liverpool St
Hobart Tasmania 7000
Secondary sponsor category [1] 287630 0
Name [1] 287630 0
Address [1] 287630 0
Country [1] 287630 0

Ethics approval
Ethics application status
Ethics committee name [1] 290763 0
Human Research Ethics Committee (Tasmania)
Ethics committee address [1] 290763 0
Office of Research Services, University of Tasmania, Private Bag 1, Hobart, TAS, 7001
Ethics committee country [1] 290763 0
Date submitted for ethics approval [1] 290763 0
Approval date [1] 290763 0
Ethics approval number [1] 290763 0

Brief summary
The purpose of this study is to define the value of strain in patient management, by identification of subclinical left ventricular (LV) dysfunction, which will be used to guide cardioprotective therapy. Who is it for? You may be eligible to join if you are aged between 18 and 80 years old (inclusive), and actively undergoing chemotherapy at increased risk of cardiotoxicity. Trial details Participants in this study will be randomly (by chance) divided into one of two groups. Participants in one group will undergo screening echocardiography for the development of cardiotoxicity with the inclusion of myocardial mechanics to measure LV strain. The measurement of LV strain will be used to guide the participant's cardioprotection treatment to avoid cardiotoxicity. Serial screening tests are envisaged to take place at 3 monthly intervals for one year with each screening session taking approximately 30 minutes. Participants in the other group will undergo standard echocardiogram and an ultrasound test of the heart where ejection fraction (EF) is measured. The measurement of EF will be used to guide the participant's cardioprotection treatment to avoid cardiotoxicity. This screening test is envisaged to take place at 3 monthly intervals for a year with each session taking approximately 30 minutes.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 47138 0
Prof Thomas H Marwick
Address 47138 0
Menzies Research Institute Tasmania 17 Liverpool St Hobart, Tas 7000
Country 47138 0
Phone 47138 0
+61 (0) 3 6226 7702
Fax 47138 0
Email 47138 0
Contact person for public queries
Name 47139 0
Prof Tomoko Negishi
Address 47139 0
Menzies Research Institute Tasmania 17 Liverpool St Hobart, Tas 7000
Country 47139 0
Phone 47139 0
+61 (0) 3 6226 7702
Fax 47139 0
Email 47139 0
Contact person for scientific queries
Name 47140 0
Prof Tomoko Negishi
Address 47140 0
Menzies Research Institute Tasmania 17 Liverpool St Hobart, Tas 7000
Country 47140 0
Phone 47140 0
+61 (0) 3 6226 7702
Fax 47140 0
Email 47140 0

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No/undecided IPD sharing reason/comment
We didn't have any consent from patients for IPD.
What supporting documents are/will be available?
No other documents available
Summary results
Have study results been published in a peer-reviewed journal?
Other publications
Have study results been made publicly available in another format?
Results – basic reporting
Results – plain English summary